youtube_live
Q3 2026 earnings • released • EPS miss -0.77% • Revenue miss -1.47%
See resultschevron_right
SYK:NYSE
Stryker Corp
$306.81
arrow_upward
+5.12%(+14.95) 1D
$306.81
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:03:37 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for SYK...
Open
$294.31
High
$307.90
Low
$293.00
Mkt. cap
117.68B
Avg. vol.
2.66M
Volume
3.74M
Dividend
1.15%
Quarterly dividend
$0.88
Ex-dividend date
Sep 30, 2026
P/E ratio
32.68
52-wk high
$389.33
52-wk low
$267.00
EPS
$9.39
Beta
0.77
Shares outstanding
383.57M
No. of employees
56K
Open
$294.31
High
$307.90
Low
$293.00
Mkt. cap
117.68B
Avg. vol.
2.66M
Volume
3.74M
Dividend
1.15%
Quarterly dividend
$0.88
Ex-dividend date
Sep 30, 2026
P/E ratio
32.68
52-wk high
$389.33
52-wk low
$267.00
EPS
$9.39
Beta
0.77
Shares outstanding
383.57M
No. of employees
56K
News stories
From web sources and news partners
News Corp
·
6 hours ago
Stryker Corp. stock outperforms competitors on strong trading day
AskTraders.com
·
6 hours ago
Stryker Shares Post Their First 5% Daily Gain in 321 Sessions of Data
Investing.com
·
14 hours ago
Stifel cuts Stryker stock price target on weak quarter, guidance
Yahoo Finance
·
2 days ago
Stryker (SYK) Stock Fair Value Falls After Analysts Reset Expectations Following Q3 Guidance
Profile
Stryker Corporation is an American multinational medical technologies corporation based in Portage, Michigan, United States. The company's products are used for medical surgery and neurotechnology, which include surgical equipment, patient and caregiver safety technologies, endoscopy systems, and patient handling, emergency medical equipment, and intensive care disposable products, as well as neurosurgical, neurovascular and oral and maxillofacial surgery implant products; and orthopedic surgery, which includes implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. Stryker's products are sold in over 75 countries and are used by 150 million patients annually. In 2024, 75% of the company's revenues came from the United States.
The company is ranked 195th on the Fortune 500 and 331st on the Forbes Global 2000. Wikipedia
About Stryker Corp
CEOKevin A. Lobo
Employees56K
Founded1941
HeadquartersKalamazoo, Michigan, United States
SectorMedical device
Websitestryker.com
Analyst ratings
Based on 21 analysts giving stock ratings to SYK in the past 3 months
Strong buy
Buy
18
Hold
3
Sell
0
12-month forecast
Based on 21 Wall Street analysts offering 12 month price targets for SYK in the last 3 months.
Highest
Current $306.81
$405.00 (+32.00%)
Average
$337.53 (+10.01%)
Lowest
$290.00 (-5.48%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Mike Kratky Leerink Partners | Buy | Maintained | $340.00 | +10.8% | 11/02/2026 |
Patrick Wood UBS | Buy | Maintained | $364.00 | +18.6% | 11/02/2026 |
Richard Newitter Truist Financial | Hold | Maintained | $305.00 | -0.6% | 11/02/2026 |
Rick Wise Stifel Nicolaus | Buy | Maintained | $325.00 | +5.9% | 11/02/2026 |
Joanne Wuensch Citi | Buy | Maintained | $315.00 | +2.7% | 11/02/2026 |
Caitlin Roberts Canaccord Genuity | Hold | Downgraded | $300.00 | -2.2% | 11/02/2026 |
Travis Steed Bank of America Securities | Buy | Maintained | - | - | 10/30/2026 |
Robbie Marcus J.P. Morgan | Buy | Maintained | $340.00 | +10.8% | 10/30/2026 |
Mathew Blackman TD Cowen | Hold | Maintained | $290.00 | -5.5% | 10/30/2026 |
Vijay Kumar Evercore ISI | Buy | Maintained | $320.00 | +4.3% | 10/30/2026 |
Vik Chopra BMO Capital | Buy | Reiterated | $309.00 | +0.7% | 10/30/2026 |
Kendall Au RBC Capital | Buy | Reiterated | $375.00 | +22.2% | 10/29/2026 |
Shagun Singh Chadha RBC Capital | Buy | Reiterated | $375.00 | +22.2% | 10/29/2026 |
Michael Matson Needham | Buy | Maintained | $359.00 | +17% | 10/30/2026 |
Matthew O'Brien Piper Sandler | Buy | Maintained | $325.00 | +5.9% | 10/30/2026 |
Jeff Johnson Robert W. Baird | Buy | Maintained | $334.00 | +8.9% | 10/30/2026 |
Ryan Zimmerman BTIG | Buy | Maintained | $304.00 | -0.9% | 10/29/2026 |
Daniel Stauder Citizens JMP | Buy | Maintained | $390.00 | +27.1% | 10/30/2026 |
Christopher Pasquale Barclays | Buy | Maintained | $365.00 | +19% | 10/30/2026 |
Matt Miksic Barclays | Buy | Maintained | $375.00 | +22.2% | 10/07/2026 |
Matthew Taylor Jefferies | Buy | Maintained | $405.00 | +32% | 09/22/2026 |
William Plovanic Canaccord Genuity | Buy | Reiterated | $385.00 | +25.5% | 09/18/2026 |
Larry Biegelsen Wells Fargo | Buy | Reiterated | $348.00 | +13.4% | 09/16/2026 |
Steven Lichtman William Blair | Buy | Reiterated | - | - | 09/09/2026 |
David Turkaly Citizens JMP | Buy | Maintained | $400.00 | +30.4% | 08/03/2026 |
Jayson Bedford Raymond James | Buy | Maintained | $370.00 | +20.6% | 07/31/2026 |
David Toung Argus Research | Buy | Reiterated | $370.00 | +20.6% | 07/09/2026 |
Unknown Analyst Wells Fargo | Buy | Maintained | $418.00 | +36.2% | 07/08/2026 |
Unknown Analyst BMO Capital | Buy | Initiated | $369.00 | +20.3% | 07/09/2026 |
David Roman Goldman Sachs | Hold | Maintained | $361.00 | +17.7% | 05/01/2026 |
Pito Chickering Deutsche Bank | Hold | Maintained | $315.00 | +2.7% | 05/01/2026 |
Lee Hambright Bernstein | Buy | Maintained | $410.00 | +33.6% | 05/01/2026 |
Nico Chen DBS | Buy | Maintained | $450.00 | +46.7% | 03/18/2026 |
Danielle Antalffy UBS | Hold | Reiterated | $380.00 | +23.9% | 03/17/2026 |
Unknown Analyst Jefferies | Buy | Maintained | $465.00 | +51.6% | 03/05/2026 |
Last report
Oct 29, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$3.52 / $3.55
-0.77%miss
arrow_downward
Revenue / Est. (USD)
6.52B / 6.62B
-1.47%miss
arrow_downward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 7.17B | 6.02B | 6.59B | 6.52B |
Cost of goods sold | 2.49B | 2.19B | 2.08B | 2.25B |
Cost of revenue | 2.49B | 2.19B | 2.08B | 2.25B |
Research and development expenses | 388.00M | 409.00M | 429.00M | 423.00M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 2.15B | 2.16B | 2.13B | 2.17B |
Operating expense | 2.72B | 2.75B | 2.73B | 2.77B |
Total operating expenses | 5.22B | 4.95B | 4.81B | 5.02B |
Operating income | 1.95B | 1.07B | 1.78B | 1.50B |
Other non operating income | -33.00M | 19.00M | 1.00M | -91.00M |
EBT including unusual items | 1.70B | 850.00M | 1.56B | 997.00M |
EBT excluding unusual items | 1.81B | 987.00M | 1.68B | 1.41B |
Income tax expense | 856.00M | 105.00M | 288.00M | 244.00M |
Effective tax rate | 50.21% | 12.35% | 18.41% | 24.47% |
Other operating expenses | - | - | - | - |
Net income | 849.00M | 745.00M | 1.28B | 753.00M |
Net profit margin | 11.84% | 12.38% | 19.37% | 11.55% |
Earnings per share | 4.47 | 2.60 | 3.69 | 3.52 |
Interest and investment income | 31.00M | 34.00M | 26.00M | - |
Interest expense | -154.00M | -148.00M | -141.00M | - |
Net interest expenses | -123.00M | -114.00M | -115.00M | - |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 2.27B | 1.37B | 2.08B | 1.79B |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events